Aster DM Healthcare Ltd (ASTERDM) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Aster DM Healthcare reported 12% revenue growth, reaching INR 4,138 crores in FY25, driven by increased inpatient volumes and ARPOB.
- Operating EBITDA grew by 30% to INR 806 crores, with EBITDA margins expanding to 19.5% due to cost discipline and operational efficiencies.
- Normalized PAT (excluding NCI and exceptional items) rose 49% to INR 357 crores.
- Q4 FY25 revenue reached INR 1,000 crores, up 2% YoY, impacted by Ramadan, fewer days in February, and lower international patient volumes.
- Despite modest Q4 revenue growth, operating EBITDA grew by 16% YoY, with margins reaching 19.3%.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.